Quand les infections conduisent-elles à un COVID prolongé? Les scientifiques se rapprochent des déclencheurs et des traitements des syndromes post-viraux

When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes Amy Proal's life changed in 2004 when she contracted an illness that left her bedridden and unable to return to school. Her symptoms, fatigue, brain fog, and persistent weakness, were initially misdiagnosed as psychiatric issues. After months of uncertainty, she was eventually diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS. This experience led her to pursue a PhD in microbiology and found PolyBio, a nonprofit dedicated to researching chronic illnesses following infections. When the coronavirus pandemic struck, Proal saw echoes of her own journey in the growing number of people suffering from long-term effects of SARS-CoV-2. Long COVID, as the condition came to be known, has affected millions globally. A 2024 study estimated that approximately 400 million individuals worldwide suffer from long-term symptoms related to the virus, with an annual economic impact of roughly $1 trillion. These figures underscore the scale of the problem, yet understanding the root causes remains elusive. Researchers are increasingly focusing on how certain immune responses might contribute to prolonged illness. Over the past several years, there has been a surge in scientific inquiry into post-acute infection syndromes. Thousands of studies have examined the biological mechanisms behind long COVID, comparing it to other conditions such as post-polio syndrome, post-Ebola syndrome, and post-treatment Lyme disease syndrome. These conditions share common features, including persistent fatigue and neurological symptoms, suggesting a shared pathway of pathophysiology. Despite these insights, definitive answers remain scarce. In 2020, the U.S. government allocated $1.15 billion to investigate the long-term impacts of SARS-CoV-2. Last year, Germany announced €500 million in funding for similar research. These investments reflect a growing recognition of the importance of understanding post-infectious conditions. However, experts argue that the financial support lags behind the severity of the issue. Chris Ponting, a geneticist at the University of Edinburgh, notes that while the pandemic has brought attention to these disorders, they remain underfunded relative to their societal impact. Researchers are striving to identify biomarkers that can reliably diagnose these conditions and guide treatment. Without clear indicators, developing effective therapies has proven challenging. While the exact pathways linking acute infections to chronic illness are not fully understood, scientists believe they are nearing critical breakthroughs. Michael Peluso, an infectious-disease clinician at the University of California, San Francisco, acknowledges the lack of a complete solution but emphasizes the accumulation of promising leads. Historically, patients experiencing prolonged symptoms after infections have often faced skepticism from medical professionals. Conditions like post-influenza exhaustion, identified by Thomas Dowse in 1894, were once dismissed as psychosomatic. The global response to the coronavirus pandemic, however, has shifted this narrative. Data from the U.S. Centers for Disease Control and Prevention indicates that about 6% of adults continue to experience long-term effects of the virus. This statistic highlights the necessity of further investigation into both prevention and treatment strategies. In early 2021, the U.S. National Institutes of Health initiated the RECOVER program, aiming to gather extensive data on individuals with long COVID. Although the initiative has faced criticism for its limited focus on therapeutic options, it has laid the groundwork for future advancements. As research continues, the hope is that clearer insights will emerge, leading to more effective interventions for those impacted by these complex and enduring conditions.